Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 59 of the 62 references it cites were found in a registry or an index.

Comparison of Sodium–Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials

Li, Wenjie, Chen, Xingqing, Xie, Xiangqi, Xu, Min, Xu, Lingling, Liu, Peiying, Luo, Bihui · 2022 · Journal of Cardiovascular Pharmacology

Abstract

Atrial fibrillation (AF) is a major public health concern with a rising prevalence. Although sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown the respective favorable effects on reducing the occurrence of AF/atrial flutter (AFL), comparative protective AF/AFL effects between above 2 novel antidiabetic agents remain unavailable. Thus, we aimed to evaluate the comparative efficacy of SGLT2is and GLP-1RAs in reducing the risk of AF/AFL in patients with type 2 diabetes and estimate relative rankings of interventions. PubMed, Embase, and ClinicalTrials.gov were searched up to December 1, 2020. All available randomized controlled trials comparing SGLT2is and GLP-1RAs with one another or placebo in patients with type 2 diabetes were included. Pooled results were shown as risk ratios (RRs) with 95% confidence intervals (CIs). We used a frequentist network meta-analysis to evaluate the outcomes of interests. Thirty-six randomized controlled trials including 85,701 participants with type 2 diabetes were identified. Compared with placebo, both SGLT2is (RR: 0.82, 95% CI, 0.68–0.99) and GLP-1RAs (RR: 0.86, 95% CI, 0.76–0.97; RR long-acting ones: 0.87, 95% CI, 0.76–0.99; RR short-acting ones: 0.72, 95% CI, 0.45–1.14) significantly reduced AF/AFL risk. No significant difference between SGLT2is and GLP-1RAs was noted (RR: 0.95, 95% CI, 0.76–1.2). Compared with placebo, results from the analysis showed an RR of 0.72 (95% CI, 0.45–1.14) for short-acting GLP-1RAs and 0.87 (95% CI, 0.76–0.99) for long-acting GLP-1RAs in reducing the risk of AF/AFL. Compared with placebo, both SGLT2is and GLP-1RAs possessed favorable effects on reducing the risk of AF/AFL. However, no difference was observed when comparisons were made between them. In addition, long-acting ones may confer a more pronounced AF/AFL reduction benefit compared with placebo.

Overview

Integrity signals

Registry

Crossref · 10.1097/fjc.0000000000001197

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 62 references

Cited by

See all 40

Metadata

Authors
Li, W., Chen, X., Xie, X., Xu, M., Xu, L., Liu, P., & Luo, B.
Affiliations
First Affiliated Hospital of Guangzhou Medical University (CN)
Corresponding author
Li, Wenjie
Venue
Journal of Cardiovascular Pharmacology
Published
2022-03
Volume
79
Issue
3
Pages
281-288
ISSN
0160-2446 (ISSN-L)
OpenAlex
W4200064002
Cited by
35
References
62
Citations by year
2026: 6 · 2025: 6 · 2024: 7 · 2023: 9 · 2022: 7
FWCI
1.00
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Cardiovascular Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
SGLT2 inhibitors, GLP-1 receptor agonists, atrial fibrillation, atrial flutter, type 2 diabetes, antidiabetic drugs, drug efficacy comparison, risk mitigation, network meta-analysis ranking
MeSH terms
Glucagon-Like Peptide Receptors, Network Meta-Analysis as Topic, Network Meta-Analysis, Sodium-Glucose Transporter 2 Inhibitors, Atrial Fibrillation, Atrial Flutter, Diabetes Mellitus, Type 2, Glucose, Humans, Hypoglycemic Agents, Sodium, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of Sodium–Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials. https://app.cochat.ai/papers/10.1097/fjc.0000000000001197
The paper
Li, W., Chen, X., Xie, X., Xu, M., Xu, L., Liu, P., & Luo, B. (2022). Comparison of Sodium–Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/fjc.0000000000001197

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.